Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
第一作者单位:[1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Lu Shun,Fang Jian,Cao Lejie,et al.Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations[J].CANCER RESEARCH.2019,79(13):doi:10.1158/1538-7445.AM2019-CT031.
APA:
Lu, Shun,Fang, Jian,Cao, Lejie,Li, Xingya,Guo, Qisen...&Su, Weiguo.(2019).Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.CANCER RESEARCH,79,(13)
MLA:
Lu, Shun,et al."Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations".CANCER RESEARCH 79..13(2019)